• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA clears automated insulin pump from Beta Bionics for type 1 diabetes

May 19, 2023 By Sean Whooley

Beta Bionics - updated logoThe FDA announced today that it cleared the Beta Bionics iLet ACE automated insulin pump and iLet dosing decision software.

FDA clearance covers the devices for people 6 years of age and older with type 1 diabetes. Combined with a compatible, FDA-cleared integrated continuous glucose monitor (iCGM), they form the iLet Bionic Pancreas. Using an algorithm, the automated insulin delivery system determines and commands insulin delivery.

iLet currently pairs with the Dexcom G6 CGM.

Former interim CEO and board member Martha Aronson last year told Drug Delivery Business News recently that the iLet will help those with diabetes reduce the cognitive burden of managing their disease.

“Today’s action will provide the type 1 diabetes community with additional options and flexibilities for diabetes management and may help to broaden the reach of AID technology,” said Dr. Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health. “The FDA is committed to advancing new device innovation that can improve the health and quality of life for people living with chronic diseases that require day-to-day maintenance like diabetes through precision medicine approaches.”

How the Beta Bionics iLet Bionic Pancreas works

The Beta Bionics iLet Bionic Pancreas uses an adaptive, closed-loop algorithm. It initializes only with a user’s body weight and requires no additional insulin dosing parameters. The algorithm removes the need to manually adjust insulin pump therapy settings and variables.

iLet also simplifies mealtime use by replacing conventional carb counting with a new meal announcement feature. This feature enables users to estimate the amount of carbs in their meal as “small,” “medium” or “large.” Over time, the algorithm learns to respond to users’ individual insulin needs.

The iLet dosing decision software determines and commands the increase, decrease, maintenance or suspension of basal insulin doses. It commands correction doses of insulin based on the input from an iCGM. The software also independently determines and commands meal doses of insulin based on the meal announcement feature.

Last year, the company reported that a trial of its iLet Bionic Pancreas met key endpoints, including reduced HbA1c. Endpoints included consistently demonstrating reduced mean HbA1c across populations regardless of race, education, or income level in exploratory analyses of subpopulations.

Adult users of the iLet Bionic Pancreas experienced a reduction in diabetes distress and fear of hypoglycemia. They demonstrated statistically significant differences relative to the standard of care group.

Beta Bionics officials offer their views

In a news release issued on Monday, May 22, Beta Bionics said it designed the iLet to alleviate the work of diabetes management in everyday life. The company also seeks to nearly eliminate the expertise required to set up and manage a traditional insulin pump.

Beta Bionics says it enables healthcare providers to spend less time with the technology and more with their patient. Sean Saint, president and CEO, says iLet “changes the paradigm of diabetes management” as the first fully automated insulin dosing system.

“This company has worked tirelessly over the past seven years to bring the first Bionic Pancreas to market. And now the iLet is here, ready to be prescribed to the T1D community and will ship imminently,” said Saint. “We hope that, for many people, the iLet helps to make diabetes a little bit easier.”

Dr. Steven Russell, chief medical officer, said the degree of automation offered by iLet relieves healthcare providers from the burden of reviewing blood glucose and CGM data in order to adjust pump settings.

Founder and executive chair Ed Damiano said clearance marks a mission more than two decades in the making. Over 23 years ago, his son first developed diabetes, leading Damiano to found the company and build the iLet platform.

“From that day, I drew motivation from him and dreamt of automating our tireless care for him so that he could have a long, healthy, and less encumbered life,” Damiano said. “Today we celebrate the dream that the iLet now fulfills. As we begin our commercial efforts to bring the iLet to the T1D community, we will continue our ongoing work on the bihormonal bionic pancreas so that we may one day deliver upon the promise that our next technology holds.”

 

This story was updated on May 22 with additional information from Beta Bionics.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance, Technology Tagged With: Beta Bionics, FDA

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS